Poliestradiola phosphate

When ATH:
L02AA02

Characteristic.

Soluble in water.

Pharmacological action.
Antitumor, estrogenic.

Application.

Prostate Cancer (for palliative care in the far advanced stages). У женщин — эстрогенная недостаточность (menopausal syndrome, and others.).

Contraindications.

Hypersensitivity, expressed human liver, thromboembolism, active thrombophlebitis, prolonged immobilization, syndrome, Dubin - Johnson, hereditary pigment gepatozy, drepanocytemia, Rotor syndrome. У женщин — беременность, lactation, menorrhagia unspecified origin, estrogen dependent tumors, endometriosis, medical history indicate jaundice and otosclerosis, develop during pregnancy.

Restrictions apply.

Chronic cardiac and renal failure, arterial hypertension, epilepsy, migraine, porphyria, cerebrovascular accident, CHD.

Side effects.

Nausea, vomiting, headache, decrease in mental performance, depression, thromboembolism, arterial hypertension, sodium and water retention, gynecomastia, decreased libido, impotence in men, allergic reactions (skin rash, bronchial obstruction, anaphylactic shock).

Dosing and Administration.

/ M (deep) - 1 once every 4 Sun. При раке предстательной железы разовая доза составляет 160–320 мг.

Precautions.

A systematic control of blood pressure, liver function, у больных сахарным диабетом — гликемического профиля.

Cautions.

Before the planned surgery, associated with an increased risk of thromboembolism, Treatment should be discontinued 6 Sun to operations. Cancel the treatment required during prolonged immobilization, the appearance of migraine headaches, sudden visual impairment (suspected retinal vein thrombosis), thrombophlebitis or thromboembolic, cholestatic hepatitis, increase blood pressure.